The latest trading session saw AbbVie (ABBV) ending at $160.46, denoting a +0.4% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.8%. Elsewhere, the Dow lost 0.76%, while the tech-heavy Nasdaq lost 1.18%.Coming into today, shares of the drugmaker had gained 10.55% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The upcoming earnings release of AbbVie will be of great interest to investors. It is antic ...

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.The good news for income investors is that several great stocks on the market continue to steadily increase their dividend payouts. Here are three top dividend growth stocks to buy in 2024.1. AbbVieWith a dividend yield of 4%, AbbVie (ABBV 0.14%) certainly attracts the attention of many income investors. However, that juicy yield doesn't tell the ful ...

Ирина Мещерякова Foreword As supplement to this article, please note that The Motley Fool, which sourced this latest list, and SureDividend both update their lists periodically. While most of this collection of 54 Kings is too pricey to justify their skinny dividends, five of the top-ten, by yield, and three more outside of the top ten, live up to the ideal of offering annual dividends (from a $1K investment) exceeding their single share prices, and this month there are four more to watch. In the curren ...

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.When it was clear a few years ago that biosimilars for AbbVie's (ABBV 1.54%) Humira would be hitting the market, management knew it had work to do. Humira is the best-selling prescription drug in history, putting AbbVie on the map. But nothing lasts forever, and the company began taking steps to ensure its future success.First, AbbVie completed the bloc ...

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively. Indeed, some key players will likely stand out in 2024 as they are backed by critical fundamentals that are likely to drive their stocks to higher valuations. In this regard, Finbold ha ...

PeopleImages/iStock via Getty Images Investment Thesis In this article, I will analyze the field of biopharma through two industry competitors: AbbVie (NYSE:ABBV, NEOE:ABBV:CA) and GSK (NYSE:GSK, OTCPK:GLAXF). I aim to illustrate the levels of their operation, which will specifically highlight AbbVie's pursuit to create medical breakthroughs and GSK's strategic abilities in the industry (and much more). We will discuss some valuation metrics to find if there is deep value in either security, too. Their ...

Maksymenko Nataliia Created by the author The S&P 500 Dividend Aristocrats Index contains 67 dividend growth [DG] stocks called the Dividend Aristocrats. With a few exceptions, the Dividend Aristocrats are S&P 500 companies with higher dividend payouts every year for 25 or more years. Based on their quality scores, I rate stocks as Exceptional (29-30), Excellent (26-28), Fine (21-25), Decent (16-20), Poor (11-15), and Inferior (0-10). Investment Grade ratings have quality scores in the range of 16-30, while ...

Drugmaker AbbVie (ABBV 0.38%) spun off from Abbott Laboratories (ABT 1.03%) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue last year -- far more than Abbott's top line, which totaled just under $44 billion.But today, AbbVie faces some challenges as its top-selling drug Humira is losing patent protection and its sales have been declining sharply. Abbott, meanwhile, isn't just some stale business. Its diabetes products have been genera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...

AbbVie Inc. (NYSE:ABBV) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer Scott Reents - Executiv ...